TRCT
AMLX icon

Tower Research Capital (TRC)’s Amylyx Pharmaceuticals AMLX Stock Holding History

Tower Research Capital (TRC)’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110K Sell
7,913
-182
-2% -$2.56K ﹤0.01% 2101
2025
Q4 		$97.8K Buy
8,095
+1,505
+23% +$20.4K ﹤0.01% 1965
2025
Q3 		$89.6K Sell
6,590
-877
-12% -$8.26K ﹤0.01% 2088
2025
Q2 		$47.9K Buy
7,467
+664
+10% +$3.23K ﹤0.01% 3015
2025
Q1 		$24.1K Sell
6,803
-39,184
-85% -$139K ﹤0.01% 2795
2024
Q4 		$174K Buy
45,987
+36,347
+377% +$171K ﹤0.01% 1812
2024
Q3 		$31.2K Sell
9,640
-22,296
-70% -$50.1K ﹤0.01% 2976
2024
Q2 		$60.7K Buy
31,936
+21,640
+210% +$41.9K ﹤0.01% 2947
2024
Q1 		$29.2K Sell
10,296
-2,018
-16% -$26.4K ﹤0.01% 2671
2023
Q4 		$181K Buy
12,314
+8,343
+210% +$128K ﹤0.01% 2184
2023
Q3 		$72.7K Sell
3,971
-295
-7% -$6.24K ﹤0.01% 2237
2023
Q2 		$92K Buy
4,266
+2,454
+135% +$66.3K ﹤0.01% 2083
2023
Q1 		$54K Sell
1,812
-86
-5% -$2.99K ﹤0.01% 2409
2022
Q4 		$70K Sell
1,898
-1,160
-38% -$41.2K ﹤0.01% 2100
2022
Q3 		$86K Sell
3,058
-282
-8% -$7.04K ﹤0.01% 2688
2022
Q2 		$64K Buy
3,340
+2,629
+370% +$31.2K ﹤0.01% 2652
2022
Q1 		$10K Buy
+711
New +$16.1K ﹤0.01% 4271

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Tower Research Capital (TRC)'s AMLX Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Amylyx Pharmaceuticals (AMLX) stake by 2.2% in Q1 2026, selling an estimated $2.56K and leaving 7,913 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #2101.

Tower Research Capital (TRC) first reported a position in AMLX in Q1 2022 and has held it in 17 quarters since. The position peaked at $181K in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Tower Research Capital (TRC) held 7,913 shares of Amylyx Pharmaceuticals worth $110K as of Q1 2026.
  • Tower Research Capital (TRC) sold 182 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $2.56K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2101 holding.
  • Tower Research Capital (TRC) first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Tower Research Capital (TRC)'s Amylyx Pharmaceuticals position peaked at $181K in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.